Funding for this research was provided by:
Sylvester Comprehensive Cancer Center (Start up fund)
Received: 23 January 2020
Accepted: 12 March 2020
First Online: 24 March 2020
Ethics approval and consent to participate
: Not applicable.
: All authors consent to publishing this data.
: University of Minnesota has a patent for Minnelide (WO/2010/129918/Triptolide Prodrugs), which has been licensed to Minneamrita Therapeutics, LLC. Dr. Sulagna Banerjee is a compensated consultant with Minneamrita Therapeutics LLC, and this relationship is managed by University of Miami. Rest of the other authors declared no conflict of interest.